The biosimilar substitution rule would apply to all enrollees, including those taking the reference product prior to the effective date of change. The update is consistent with requests from ASHP to encourage biosimilar adoption. However, “State legislatures will need to move quickly to empower pharmacists to implement substitutions of lower-cost biosimilar products in order to avoid dramatic increases in patient cost sharing from this Medicare policy,” Tom Kraus, ASHP vice president of government relations, said in the article.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
